Many people with CF require frequent hospitalizations and continuous use of antibiotics, enzyme supplements, and other medications. Due to medical advances, the median life expectancy is just under 30 years and for children born today that is improving. Doctors at Vanderbilt University Medical Center are studying an experimental vaccine to prevent RSV in CF patients. The vaccine, called Purified Fusion Protein or PFP-3, is manufactured by Wyeth Lederle. The study is a double-blind randomized trial using a placebo so patients are given either the drug or a placebo.
Side effects are mild ranging from minor reactions at the site of the injection to a headache.
The Vanderbilt site is testing the vaccine in 17 children ranging in age from one to 13. Eighteen centers around the country are testing a total of 289 patients. While the results are not yet released, doctors do know that based on previous results the vaccine may be effective. Copyright 2000 by TheCarolinaChannel. All rights reserved.